T1	Condition 0 15	Type 1 diabetes
T2	Measurement 17 29	autoantibody
T3	Value 30 38	positive
R1	Has_value Arg1:T2 Arg2:T3	
R2	Subsumes Arg1:T1 Arg2:T2	
T4	Drug 67 82	GLP-1 analogues
T5	Drug 86 117	dipeptidyl peptidase inhibitors
*	OR T4 T5
T6	Scope 67 117	GLP-1 analogues or dipeptidyl peptidase inhibitors
T7	Temporal 118 133	within 6 months
R3	Has_temporal Arg1:T6 Arg2:T7	
T8	Condition 148 161	heart failure
T9	Qualifier 141 147	severe
R4	Has_qualifier Arg1:T8 Arg2:T9	
T10	Measurement 177 181	NYHA
T11	Value 182 183	4
R5	Has_value Arg1:T10 Arg2:T11	
R6	Subsumes Arg1:T8 Arg2:T10	
T12	Condition 186 204	Active myocarditis
T13	Device 221 243	artificial heart valve
T14	Qualifier 206 220	malfunctioning
R7	Has_qualifier Arg1:T13 Arg2:T14	
*	OR T12 T13
T15	Condition 257 280	ventricular tachycardia
T16	Temporal 281 296	within 3 months
R8	Has_temporal Arg1:T15 Arg2:T16	
T17	Condition 328 363	third-degree atrioventricular block
T18	Condition 317 324;334 363	second- degree atrioventricular block
*	OR T17 T18 T15
T19	Measurement 373 396	systolic blood pressure
T20	Qualifier 366 372	Supine
R9	Has_qualifier Arg1:T19 Arg2:T20	
T21	Value 397 406	<85 mm Hg
T22	Value 410 420	>200 mm Hg
*	OR T21 T22
T23	Scope 397 420	<85 mm Hg or >200 mm Hg
R10	Has_scope Arg1:T19 Arg2:T23	
T24	Condition 436 460	Primary renal impairment
T25	Measurement 462 482	creatinine clearance
T26	Value 483 494	< 45 ml/min
T27	Drug 511 520	metformin
R11	AND Arg1:T24 Arg2:T27	
R12	AND Arg1:T24 Arg2:T25	
R13	Has_value Arg1:T25 Arg2:T26	
T28	Condition 535 546	hypokalemia
T29	Condition 550 562	hyperkalemia
*	OR T28 T29
T30	Measurement 564 573	potassium
T31	Value 574 585	<3.5 mmol/l
T32	Value 589 600	>5.5 mmol/l
*	OR T31 T32
T33	Scope 574 600	<3.5 mmol/l or >5.5 mmol/l
R14	Has_scope Arg1:T30 Arg2:T33	
T34	Scope 535 562	hypokalemia or hyperkalemia
R15	Subsumes Arg1:T34 Arg2:T33	
T35	Condition 616 622	anemia
T36	Qualifier 604 615	Significant
R16	Has_qualifier Arg1:T35 Arg2:T36	
T37	Measurement 624 626	Hb
T38	Value 627 635	< 90 g/l
R17	Has_value Arg1:T37 Arg2:T38	
R18	Subsumes Arg1:T35 Arg2:T37	
T39	Condition 645 669	gastrointestinal disease
T40	Qualifier 638 644	Severe
R19	Has_qualifier Arg1:T39 Arg2:T40	
T41	Condition 681 694	gastroparesis
R20	Subsumes Arg1:T39 Arg2:T41	
T42	Measurement 728 743	Body mass index
T43	Measurement 745 748	BMI
T44	Value 750 760	> 45 kg/m2
R21	Subsumes Arg1:T42 Arg2:T43	
R22	Has_value Arg1:T42 Arg2:T44	
T45	Condition 763 781	Malignant neoplasm
T46	Procedure 792 804	chemotherapy
T47	Procedure 806 813	surgery
T48	Procedure 815 824	radiation
T49	Procedure 828 846	palliative therapy
T50	Temporal 854 871	previous 5 years.
*	OR T46 T47 T48 T49
T51	Scope 792 846	chemotherapy, surgery, radiation or palliative therapy
R23	Has_scope Arg1:T45 Arg2:T51	
R24	Has_temporal Arg1:T45 Arg2:T50	
T52	Negation 1008 1015	allowed
T53	Condition 886 925	intraepithelial squamous cell carcinoma
T54	Qualifier 933 937	skin
R25	Has_qualifier Arg1:T53 Arg2:T54	
T55	Drug 951 962	topical 5FU
R26	AND Arg1:T53 Arg2:T55	
T56	Condition 981 1003	basal cell skin cancer
*	OR T53 T56
T57	Scope 886 1003	intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer
R27	Has_negation Arg1:T57 Arg2:T52	
T58	Pregnancy_considerations 1037 1133	Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant
T59	Condition 1153 1166	alcohol abuse
T60	Condition 1144 1148;1161 1166	drug abuse
*	OR T59 T60
T61	Condition 1180 1185;1197 1209	acute pancreatitis
T62	Condition 1189 1209	chronic pancreatitis
*	OR T62 T61
T63	Non-query-able 1211 1281	Subjects considered by the Investigator to be unsuitable for the study
